Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). - Wikidata - awgldk - TriplyDB

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

http://www.wikidata.org/entity/Q33658636

about

Critical appraisal of trastuzumab in treatment of advanced stomach cancer Clinical modalities for management of gastric cancer hepatic metastasis Gastric cancer: The times they are a-changin'Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy Novel immunotherapeutic strategies of gastric cancer treatment Gastric Cancer: New Drugs - New Strategies Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers.Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer.Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer.Molecular confocal laser endomicroscopy: a novel technique for in vivo cellular characterization of gastrointestinal lesions Clinical impact of tumour biology in the management of gastroesophageal cancer Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Targeted therapies for gastric cancer: current status.Molecular targeting to treat gastric cancer.Treatment options in patients with metastatic gastric cancer: current status and future perspectives Current status of novel agents in advanced gastroesophageal adenocarcinoma.Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction EPMA position paper in cancer: current overview and future perspectives.Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis.Targeted therapy in gastroesophageal cancers: past, present and future.A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma Targeted therapies in gastric cancer and future perspectives.Immunotherapy for gastrointestinal malignancies.Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy.Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.New and emerging combination therapies for esophageal cancer.A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.The progress of targeted therapy in advanced gastric cancer RANKL/RANK pathway abrogates cetuximab sensitivity in gastric cancer cells via activation of EGFR and c-Src.Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard?Targeted therapies for metastatic esophagogastric cancer Anti-HER agents in gastric cancer: from bench to bedside.Evolving standards of care in advanced gastric cancer.Molecular targeted agents for gastric and gastroesophageal junction cancer.Current status of targeted therapies in advanced gastric cancer.Novel targeted agents for gastric cancer.Targeted therapy for gastric cancer--current status.Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?

P2860

Q24604411-77871832-8B06-4950-B123-9A154A05D92F Q26765314-BCA8D306-D0F4-4E65-94BC-C2BE2217C089 Q26776195-E0FF0EA5-1FF0-4E60-9CB4-41BE2B00B9CE Q26798420-D279017E-2395-477E-9F34-C6838315AC79 Q27011232-EE47E00E-ED28-474F-A597-A434ED770ED0 Q27028079-87091254-62B6-45E8-8B70-B9C27E763BF2 Q33422778-154C6DA2-C030-48DA-9BBE-22E78069E830 Q33574315-2D9BA323-5D0A-4443-8761-7C4A63456F66 Q33609291-6BA58C3D-87D9-4263-B4BF-5961A00676B8 Q33801366-B934B3AF-D6C9-4234-A2A7-25B17B4D4CCF Q33922534-11DBF75F-9096-4CAB-A510-B77C89B8F97D Q34094855-F90B3361-64BF-497E-857C-5FC983DBB9E0 Q34205672-2BE8F3D0-DB8B-4200-863E-614A6ABC13F2 Q34326593-E6CB02BA-C469-4041-8369-60A4CC49C086 Q34661367-90F4589B-327B-4900-91B2-54E70C17E6CA Q34962039-72FE58D4-754C-4030-B60A-4EA3F8A3F9A1 Q35208151-7D8AF940-557B-49EA-8246-1B55391B94A2 Q35532215-02FD5785-0FEA-48A4-8486-9E5D2A0CD0D8 Q35863874-121C5E7C-349F-4873-98B3-35102751EF8A Q36194219-941EA30D-B73E-418C-9D11-6F2FE879AE0D Q36210986-AF5F860F-48D7-4A1C-9E5B-A44E5BD17658 Q36294579-C0CF6F8F-EDE6-4DAE-8C66-69B9695670F0 Q36383409-8DBA7884-E899-4CF5-9FE8-F42D8BBE3CF0 Q36471685-BB947222-B047-4953-85ED-2D88180A698A Q36602174-828AC4DA-2BF3-4FE9-A0F3-8A70B94ED049 Q36638061-0DB09379-4F1C-4478-84C1-7F7CBA059276 Q36892840-FD1E9A5E-FE7F-45B6-9C7D-59C3138BC79A Q36996728-3B325F83-9287-467B-BC0B-6A1CB5572B83 Q37240838-9A1618E6-54B0-4F1F-9030-2262BBA6632B Q37427269-7A42520D-C991-49E0-B50D-F98CB59FDA9C Q37582762-AA35FFE2-7C86-42CE-8355-787B3F39C731 Q37832986-C36B24B6-8393-47B0-9141-96FD74F9EBA7 Q37836513-1E6DD5B5-3AAE-4CE2-AF84-581210A602ED Q37885725-8DD75652-3AA4-4717-B72F-48EF13915675 Q37960206-9F9104E1-3DC5-432B-B0AA-F886237C6C3B Q37962816-2A41BE20-6534-482B-918E-A379501557CD Q37996448-361B6787-725B-4044-906E-A3FA5589F1F3 Q38019657-0D51518B-8FEB-42AB-9C76-798765ECAA8F Q38019898-7867726A-D27E-4A7F-8E5B-B548F2CE249E Q38074157-33D9E181-16AE-40B8-9AAE-F887D2E6BC31

P2860

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

http://www.wikidata.org/entity/Q33658636

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Cetuximab plus oxaliplatin/leu ...... nternistische Onkologie (AIO).

@ast

Cetuximab plus oxaliplatin/leu ...... nternistische Onkologie (AIO).

@en

type

label

Cetuximab plus oxaliplatin/leu ...... nternistische Onkologie (AIO).

@ast

Cetuximab plus oxaliplatin/leu ...... nternistische Onkologie (AIO).

@en

prefLabel

Cetuximab plus oxaliplatin/leu ...... nternistische Onkologie (AIO).

@ast

Cetuximab plus oxaliplatin/leu ...... nternistische Onkologie (AIO).

@en

P1433

Q33658636-5E3DDC73-8D14-482F-BC22-C6DBEFABA59E

P1476

Q33658636-CC8696F1-9926-46DC-B52F-2407B9F0D1E6

P2093

Q33658636-068A519E-4E4B-411C-A8CD-F22AA1CF635C

Q33658636-2BAFD81D-A206-40B4-97AD-5C72BE1BEB21

Q33658636-3134EAA4-9F76-4043-BD0E-ADFF2B410593

Q33658636-3F430709-57D1-4A3D-8007-A8E9F1C56AB1

Q33658636-42487578-0407-4DAD-A061-5CCD71F87C5C

Q33658636-424EA171-FB17-44D2-8CC1-EB86A4869BC2

Q33658636-42776239-55FD-4B53-B5DF-418F81192CD8

Q33658636-7209B75F-54E5-4095-949D-B1F34538A6FF

Q33658636-87697EA7-5838-4506-B15A-E569F4B59B45

Q33658636-92923B22-35DF-4340-93A2-6356678FD4C8

P2860

Q33658636-0675918E-8B6A-49AF-95AF-D8B827B1E140

Q33658636-076E8E10-9AD0-4A88-B856-C99C6162A38D

Q33658636-151BB798-E13F-4489-B267-1E3A54A4FE80

Q33658636-15A5DAA2-21B6-4999-B07E-BDFE90B335D2

Q33658636-19C06DE3-5688-486C-B946-451638CCE195

Q33658636-1BEB03B5-5D47-448F-BF98-7D8E14ED6D5C

Q33658636-1D5B8EBC-77E1-4F1E-A4DA-FB666ACD0ADF

Q33658636-2445816B-418A-4730-B608-2A7BFF2A4183

Q33658636-266D9B72-6C66-4161-9EDC-EE8FC782F392

Q33658636-3D567D95-DE9F-4939-833E-AFEE314465E3

P2888

Q33658636-7D78C7C4-DDB0-4095-A8E3-CC1612ECA076

P304

Q33658636-68EDBFB6-A314-4463-B869-D4CCE5E418F5

P31

Q33658636-F7651CBD-B4AC-415F-ACCE-0DECFF85F65A

P356

Q33658636-06E39644-35F5-45DB-9F1F-2E9A78B13005

P407

Q33658636-1D2E873B-64CA-4381-B2B8-BE0BA24D87FB

P433

Q33658636-2BACA432-3F28-4F57-AD1F-C1D871CA3D91

P478

Q33658636-13EADEA2-506A-4320-99B2-4DD290D09F48

P577

Q33658636-CA76F404-CDDE-47BE-AF4B-3BE13FC93C54

P5875

Q33658636-FCCF718E-6638-4479-9EFA-66746DC8517C

P6179

Q33658636-FBE60BB6-D198-4AED-99A3-D0DFEE90E3B4

P698

Q33658636-45850DE5-1535-44D6-9891-306CB160E0A9

P921

Q33658636-78169277-A844-453B-AB86-C9A8AC6A8C7C

P932

Q33658636-338D074E-C26E-4144-9BD5-728FCEBF6272

P356

P1433

British Journal of Cancer

P1476

Cetuximab plus oxaliplatin/leu ...... nternistische Onkologie (AIO).

@en

P2093

B Luber

http://www.w3.org/2001/XMLSchema#string

C Peschel

http://www.w3.org/2001/XMLSchema#string

E Endlicher

http://www.w3.org/2001/XMLSchema#string

E Wöll

http://www.w3.org/2001/XMLSchema#string

F Fend

http://www.w3.org/2001/XMLSchema#string

F Lordick

http://www.w3.org/2001/XMLSchema#string

G Folprecht

http://www.w3.org/2001/XMLSchema#string

G Keller

http://www.w3.org/2001/XMLSchema#string

N Röthling

http://www.w3.org/2001/XMLSchema#string

S Hegewisch-Becker

http://www.w3.org/2001/XMLSchema#string

P2860

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

EGFR antagonists in cancer treatment

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

P2888

P304

500-505

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605521

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41001194

http://www.w3.org/2001/XMLSchema#string

P6179

1003673412

http://www.w3.org/2001/XMLSchema#string

P698

20068568

http://www.w3.org/2001/XMLSchema#string

P921

P932

2822949

http://www.w3.org/2001/XMLSchema#string